search
Back to results

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI)

Primary Purpose

Squamous Cell Carcinoma

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Onivyde
Paclitaxel
Sponsored by
Federation Francophone de Cancerologie Digestive
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Squamous Cell Carcinoma focused on measuring ESCC NAL-IRI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically proven metastatic oesophageal squamous cell carcinoma
  • Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients presenting with resectable disease treated with surgery or neoadjuvant or adjuvant chemotherapy with oxaliplatin or cisplatin (with or without radiotherapy) can be included if a recurrence has occurred less than 6 months after the end of treatment
  • Age ≥ 18 years
  • Unresectable disease, measurable or not, according to RECIST 1.1 criteria
  • WHO performance status ≤ 2
  • Neutrophils ≥ 1500/mm3 (without use of haematopoietic growth factors), platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl (blood transfusions are authorised for patients with a haemoglobin less than 9 g/dl)
  • Total bilirubin ≤ 2 x ULN (biliary drainage is authorised in case of a biliary obstruction); albumin ≥ 25 g/L; AST ≤ 2.5 x ULN, and ALT ≤ 2.5 x ULN (≤ 5 x ULN in case of hepatic metastases)
  • Creatinine clearance ≥ 50 ml/min according to MDRD formula
  • A normal ECG or ECG with no clinically significant findings
  • Patient able to understand and to sign the informed consent form (or who has a legal guardian able to do so for him/him)
  • Women of childbearing potential must have a negative pregnancy blood or urine test within 7 days prior to inclusion
  • Women of childbearing potential, as well as men (who have sexual relations with women of childbearing potential) must agree to use an effective method of contraception throughout this study and during the 6 months following administration of the last dose of the study medicinal product
  • Patient who is a beneficiary of the Social security system
  • Patient for whom regular follow-up is possible.

Exclusion Criteria:

  • Known brain or bone metastases
  • Clinically significant gastrointestinal disorders, including hepatic, haemorrhagic, inflammatory, obstructive disorders or diarrhoea > grade 1
  • History of chronic inflammatory bowel disease
  • Gilbert's syndrome
  • Interstitial lung disease
  • Treatment with St John's Wort
  • Medical history of Whipple procedure
  • Body mass index < 18.5 kg/m2
  • Combination with sorivudine and others analogues as brivudine (irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase)
  • History of progressive cancer or in remission of less than 3 years duration (patients who present with a cancer in situ or basal cell or squamous cell skin cancer during the last 3 years are eligible).
  • Severe arterial thromboembolic events (myocardial infarction, unstable angina, stroke) less than 3 months before inclusion
  • NYHA class III or IV congestive heart failure, ventricular arrhythmia or uncontrolled blood pressure
  • Significant neuropathy ≥ grade 2 according to NCI CTCAE criteria (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.0.
  • Known hypersensitivity or allergy to a component of the medicinal products used in the study.
  • Known DPD deficiency

Sites / Locations

  • Chu AmiensRecruiting
  • Institut Sainte CatherineRecruiting
  • Hopital EuropéenRecruiting
  • Ch Le RaincyRecruiting
  • Chu Saint LouisRecruiting
  • Ch PerpignanRecruiting
  • Chu de PoitiersRecruiting
  • Chu RouenRecruiting
  • Ch DuchenneRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

arm A: ONIVYDE

Arm B: TAXOL

Arm Description

ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours

TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15

Outcomes

Primary Outcome Measures

survival at 9 months
The principal objective is to evaluate survival at 9 months in patients presenting with metastatic oesophageal squamous cell carcinoma (OSC) treated with Nal-IRI/LV5-FU or with paclitaxel.

Secondary Outcome Measures

Progression-free survival
Clinical Progression-free survival and/or radiological Progression free survival will be evaluated
Overall survival (OS)
evaluate the overall survival
Best response rate during treatment
Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and with centralised review)
Toxicity (NCI-CTC v4)
all observed toxicities, graded according to NCI-CTC v4 and the SAE
Quality of life (questionnaires)
Quality of life (QLQ-C30 questionnaires of EORTC) and OES18 questionnaires of EORTC

Full Information

First Posted
September 26, 2018
Last Updated
August 16, 2023
Sponsor
Federation Francophone de Cancerologie Digestive
Collaborators
Shire
search

1. Study Identification

Unique Protocol Identification Number
NCT03719924
Brief Title
Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
Acronym
OESIRI
Official Title
Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 7, 2019 (Actual)
Primary Completion Date
April 15, 2024 (Anticipated)
Study Completion Date
April 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Federation Francophone de Cancerologie Digestive
Collaborators
Shire

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of our study is to evaluate the efficacy and safety of NALIRI plus 5FU versus paclitaxel as a second-line therapy in patients with locally advanced or metastatic ESCC who had failed to cisplatin- or oxaliplatin-based first-line chemotherapy. The hypotheses are as follows: H0: the percentage of patients alive at 9 months of 40% is not useful. H1: the percentage of patients alive at 9 months of 60% is expected.
Detailed Description
Principal objective: • To evaluate the survival of patients at 9 months Secondary objectives: Progression-free survival (PFS) (clinical and/or radiological) Overall survival (OS) Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and the centralised review committee) Toxicity (NCI CTC 4.0) Quality of life (QLQ-C30 and OES18 questionnaires of the EORTC) Arm A (experimental arm): Nal IRI plus LV5-FU (D1=D28) Nal-IRI: 80 mg/m² intravenous over 90 minutes Followed by intravenous folinic acid 400 mg/m² over 30 minutes or L-folinic acid: 200 mg/m² over 30 minutes And then 5-FU 2,400 mg/m² over 46 hours on D1 to D14 Patients known to be homozygous for the UGT1A1*28 allele who are to be randomized to the Nal-IRI/5-FU Arm receive the first cycle of therapy with a reduced dose of Nal IRI of 60 mg/m2. If the patient does not present any toxicity related to the medicinal product after the first administration of Nal IRI, the dose can be increased to 80 mg/m2 starting with cycle 2. Arm B (control arm): PACLITAXEL (D1=D28) Paclitaxel: 80 mg/m² at D1, D8 and D15 Patients will be randomized in a 1:1 ratio using the minimisation technique. Randomisation will be stratified based on the following factors: Centre WHO performance status: 0/1 versus 2 An analysis of circulating tumour DNA (using genetic mutations, in particular, TP53, and DNA methylation analyses) will be performed before the 1st cycle of treatment and at D28, in order to look for factors predictive of response to treatment (decrease in unbound DNA).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Squamous Cell Carcinoma
Keywords
ESCC NAL-IRI

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
All initial characteristics will be described in the overall population and by treatment arm. Evaluation criteria related to efficacy and safety will be described by treatment arm. Initial characteristics of best response and toxicities will be evaluated using usual statistics: for quantitative variables: mean, standard deviation, median, interquartile interval and range and for qualitative variables: frequencies and percentages. For the primary evaluation end point, a one-sided 95% confidence interval (CI) will be calculated in the experimental arm.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
106 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
arm A: ONIVYDE
Arm Type
Experimental
Arm Description
ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
Arm Title
Arm B: TAXOL
Arm Type
Active Comparator
Arm Description
TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
Intervention Type
Drug
Intervention Name(s)
Onivyde
Other Intervention Name(s)
no other intervention name to add
Intervention Description
onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Other Intervention Name(s)
no other intervention name to add
Intervention Description
Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
Primary Outcome Measure Information:
Title
survival at 9 months
Description
The principal objective is to evaluate survival at 9 months in patients presenting with metastatic oesophageal squamous cell carcinoma (OSC) treated with Nal-IRI/LV5-FU or with paclitaxel.
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Progression-free survival
Description
Clinical Progression-free survival and/or radiological Progression free survival will be evaluated
Time Frame
5 years
Title
Overall survival (OS)
Description
evaluate the overall survival
Time Frame
1 year
Title
Best response rate during treatment
Description
Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and with centralised review)
Time Frame
6 months
Title
Toxicity (NCI-CTC v4)
Description
all observed toxicities, graded according to NCI-CTC v4 and the SAE
Time Frame
6 months
Title
Quality of life (questionnaires)
Description
Quality of life (QLQ-C30 questionnaires of EORTC) and OES18 questionnaires of EORTC
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically proven metastatic oesophageal squamous cell carcinoma Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients presenting with resectable disease treated with surgery or neoadjuvant or adjuvant chemotherapy with oxaliplatin or cisplatin (with or without radiotherapy) can be included if a recurrence has occurred less than 6 months after the end of treatment Age ≥ 18 years Unresectable disease, measurable or not, according to RECIST 1.1 criteria WHO performance status ≤ 2 Neutrophils ≥ 1500/mm3 (without use of haematopoietic growth factors), platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl (blood transfusions are authorised for patients with a haemoglobin less than 9 g/dl) Total bilirubin ≤ 2 x ULN (biliary drainage is authorised in case of a biliary obstruction); albumin ≥ 25 g/L; AST ≤ 2.5 x ULN, and ALT ≤ 2.5 x ULN (≤ 5 x ULN in case of hepatic metastases) Creatinine clearance ≥ 50 ml/min according to MDRD formula A normal ECG or ECG with no clinically significant findings Patient able to understand and to sign the informed consent form (or who has a legal guardian able to do so for him/him) Women of childbearing potential must have a negative pregnancy blood or urine test within 7 days prior to inclusion Women of childbearing potential, as well as men (who have sexual relations with women of childbearing potential) must agree to use an effective method of contraception throughout this study and during the 6 months following administration of the last dose of the study medicinal product Patient who is a beneficiary of the Social security system Patient for whom regular follow-up is possible. Exclusion Criteria: Known brain or bone metastases Clinically significant gastrointestinal disorders, including hepatic, haemorrhagic, inflammatory, obstructive disorders or diarrhoea > grade 1 History of chronic inflammatory bowel disease Gilbert's syndrome Interstitial lung disease Treatment with St John's Wort Medical history of Whipple procedure Body mass index < 18.5 kg/m2 Combination with sorivudine and others analogues as brivudine (irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase) History of progressive cancer or in remission of less than 3 years duration (patients who present with a cancer in situ or basal cell or squamous cell skin cancer during the last 3 years are eligible). Severe arterial thromboembolic events (myocardial infarction, unstable angina, stroke) less than 3 months before inclusion NYHA class III or IV congestive heart failure, ventricular arrhythmia or uncontrolled blood pressure Significant neuropathy ≥ grade 2 according to NCI CTCAE criteria (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.0. Known hypersensitivity or allergy to a component of the medicinal products used in the study. Known DPD deficiency
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
DAVID TOUGERON
Phone
05.49.44.37.51
Ext
42109
Email
David.TOUGERON@chu-poitiers.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DAVID TOUGERON
Organizational Affiliation
PRODIGE 62 - FFCD 1701
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu Amiens
City
Amiens
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
VINCENT HAUTEFEUILLE
Facility Name
Institut Sainte Catherine
City
Avignon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
laurent mineur
Facility Name
Hopital Européen
City
Marseille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yves rinaldi
Facility Name
Ch Le Raincy
City
Montfermeil
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
IDA PAVESE
Facility Name
Chu Saint Louis
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
THOMAS APARICIO
Facility Name
Ch Perpignan
City
Perpignan
Country
France
Individual Site Status
Recruiting
Facility Name
Chu de Poitiers
City
Poitiers
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DAVID TOUGERON, PR
Facility Name
Chu Rouen
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PIERRE MICHEL
Facility Name
Ch Duchenne
City
Saint-Malo
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ROMAIN DESGRIPPES

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31899122
Citation
Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lievre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Dig Liver Dis. 2020 Mar;52(3):347-350. doi: 10.1016/j.dld.2019.11.014. Epub 2019 Dec 30.
Results Reference
background

Learn more about this trial

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

We'll reach out to this number within 24 hrs